03-04-2012: Ablynx announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® licensed to Novartis. This is the first development candidate emerging from the licensing agreement between Ablynx and Novartis.
Ablynx and Novartis entered into a commercial licensing agreement in July 2010, under which Novartis obtained licenses to develop and commercialise Nanobodies against two targets (including this one for which an IND has been approved), which originated from the research agreement between the parties, entered into in 2005. Since July 2010, Novartis has full responsibility for the continued progress of both programmes and Ablynx is eligible to receive development-based milestone payments and royalties on sales following commercialisation of the products.
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are excited that Novartis has obtained IND approval and that they will bring this first Nanobody into clinical development in an oncology setting. This development candidate demonstrates the power of the Nanobody platform in addressing complex target classes that are challenging to address with conventional antibodies."
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.Under the terms of the coll ... more
Ablynx announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company's forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.Dr Perlmutter was Executive Vice President, Research an ... more
Ablynx announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically designed by Ablynx for direct lung delivery, via a nebuliser, to treat respiratory syncytial virus (RSV) infections.Th ... more
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currentl ... more
Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology. Under the terms of the agreement, Oxford BioMedica will also provide certain process development services ... more
Evotec AG announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis. No financial details were given.
Under the terms of the agreement, Evotec is responsible for progressing the program up to pre-clinical development and Novartis will then h ... more
Novartis and the University of Pennsylvania (Penn) announced an exclusive global collaboration to research, develop and commercialize targeted chimeric antigen receptor (CAR) immunotherapies for the treatment of cancers. In addition, the parties will jointly establish a new research and dev ... more
We focus on the well-being of companion animals and the health and productivity of farm animals. Our extensive product range provides solutions for the prevention and treatment of various widespread animal diseases and parasite infestations. The majority of these products are available by p ... more